GE Healthcare said today it has acquired Asymptote to have an undisclosed price in a deal that the buyer said might strengthen its cell therapy portfolio with technologies made to enable the cryopreservation of cellular materials.
Asymptote specializes in cryochain technology for sensitive cellular remedies, with the goal of significantly lowering the risk of contamination present in conventional processes.
The company’ s included suite of cryochain hardware, software, and consumables is made to support cGMP and maintain the potency of cellular therapies by allowing ultra-low-temperature freezing during production, followed by thawing prior to applying to patients in clinical settings.
Asymptote’ s VIA Freeze TM variety delivers liquid nitrogen-free cryopreservation, while the soon-to-be released THROUGH Thaw TM series thaws seriously frozen cells using a dry conduction (water-free) process. The particular company’ s web-based my. Cryochain software platform is made to support cell therapy companies as they scale their cryopreservation and thawing processes by synchronizing with the VIA Deep freeze and VIA Thaw products to standardize freezing plus thawing programs across multiple sites, improving the presence of remote processes.
“ Asymptote’ h high-quality offering takes us another step forward in our eyesight to industrialize cell therapy, and in providing reliable plus high-quality services for our customers and patients around the world, ” Ger Brophy, Ph. D., general manager of GENERAL ELECTRIC Healthcare’ s cell therapy business, said in a declaration.
Added Asymptote founder and CEO Ruben Morris, Ph. D.: “ The acquisition gives all of us the opportunity to reach a larger audience through the local specialist GENERAL ELECTRIC Cell Therapy team, provides us with a strong system for our product launches, and allows us to significantly scale upward our product development. ”
GE Healthcare factors that demand for manufacturing and clinical delivery increases as the cell therapy market grows and develops. The organization cited statistics from the Alliance for Regenerative Medicine displaying 804 clinical trials underway by the end of last year to get cell therapies, as well as gene-modified cell therapies, gene remedies, and tissue-engineering therapies.
The acquisition of Annäherungslinie is GE Healthcare’ s latest move toward increasing its cell therapy offerings. In July 2016, GENERAL ELECTRIC acquired Biosafe Group, a supplier of integrated cellular bioprocessing systems, for an undisclosed sum. Three months earlier, GENERAL ELECTRIC Ventures teamed up with Mayo Clinic Ventures to release Vitruvian Networks, a collaboration providing cloud-based software program systems and manufacturing services for cell and gene therapies.
And in January 2016, GE Health care and the Government of Canada each committed C$20 mil ($15 million) to launch the [email protected] Cell Therapy Centre of Excellence, created to promote brand new technologies for the production of cellular therapies in Toronto.